The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.
Result: The Q151M MDR mutations were also genetically linked to NRTI mutations M184IV and L210F, and NNRTI mutations E138A, Y181I and H221Y (Table 1).
Result: The effect on susceptibility to 3TC was probably due to M184I/V mutations which were seen by 4 months.
Result: The patient-derived RT at 4 months had already developed the M184I mutation which is known to affect viral replicative fitness.
High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo.
PMID: 21663632
2011
Journal of the International AIDS Society
Table: M184I
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.
PMID: 21694608
2011
Journal of acquired immune deficiency syndromes (1999)
Abstract: nonnucleoside reverse transcriptase inhibitor-DRM were found in 17 of 36 (47.2%) efavirenz recipients, and M184V/I mutation in 14 of 40 (35.0%) lamivudine recipients.
Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load.
Abstract: We found that causal effect estimates of mutations M184V/I (-1.7 log10pVL) and D67N/G (-2.1[3 CD4] and 0.4 log10pVL) were compensated by K103N/S and K219Q/E/N/R.
Discussion: Even so, the effect of M184V/I on viral fitness in vivo is confounded by the effects of other SDRMs and demographic/risk factors that should be handled using a causal modeling approach.
Discussion: Of all position-specific effects of SDRMs on baseline prognostic markers inferred from these data, one of the largest and most statistically significant was M184V/I.
Discussion: On the other hand, experimental studies of M184V/I-containing recombinant HIV-1 are potentially not subject to these confounding
Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: an observational cohort study in rural China.
PMID: 21725248
2011
Journal of acquired immune deficiency syndromes (1999)
Abstract: M184V/I was the most common nucleoside reverse transcriptase inhibitor resistance mutation at 77.6%, the mutation rate for >=3 thymidine analogue mutations, Q151M, and K65R were 33%, 12%, and 9%, respectively.
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
PMID: 21765365
2011
Journal of acquired immune deficiency syndromes (1999)
Discussion: Mutations encoding M184I/V have been reported across studies of pregnant and postpartum women.
Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.
PMID: 21791652
2011
The Journal of infectious diseases
Abstract: The most common mutations were M184I/V (14 cases), K103N (9), and M230L (3).
Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.
Abstract: Enzymatic 3TC resistance correlated well with the presence of M184I/V, and reduced NVP susceptibility was strongly associated with the presence of K103N, Y181C/I, Y188L, and G190A/Q.
Result: Of the 74 samples with phenotypic resistance to 3TC, 70 (94%) had the M184 V or M184I mutations.
Table: M184V/I
Discussion: We demonstrate that enzymatic 3TC resistance was strongly associated with M184I/V.
The glutamine side chain at position 91 on the beta5a-beta5b loop of human immunodeficiency virus type 1 reverse transcriptase is required for stabilizing the dNTP binding pocket.
Result: Resistant variants containing an M184I alteration in RT gene appear transiently and then are replaced by those with M184V alteration.
Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
Abstract: Also reported are associations of therapy choice, prolonged virologic failure, and concurrent HIV viral load and CD4 count with the presence of M184I/V, TAMs, K65R, and resistance to ETV.
Abstract: In order to describe resistance patterns by genotypic testing, at the time of first-line ART failure and to describe associations with having M184I/V, K65R, three or more thymidine analog mutations (TAMs) and etravirine (ETV) resistance, the prevalence of antiretroviral drug resistance associated mutations in a cross-sectional study, at two South African public health clinic settings, at the time of virologic failure (HIV-1 RNA load >400 copies/ml) are described.
Abstract: Of 167 adult patients with virologic failure on first-line ART, 28 (17%) had no resistance, 137 (82%) had NNRTI resistance
HIV mutation literature information.
PMID: 
2011
Retrovirology
Browser Board
Co-occurred Entities
Filtrator
ViMRT